Efficacy, Safety and Cost of Regorafenib in Patients with Metastatic Colorectal Cancer in French Clinical Practice

BACKGROUND: Regorafenib is an orally administered multikinase inhibitor that has been approved for patients with chemotherapy-refractory metastatic colorectal cancer (mCRC). Even though regorafenib significantly improved survival in two international phase 3 trials (CORRECT and CONCUR), a high rate...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Clin Med Insights Oncol
Main Authors: Calcagno, Fabien, Lenoble, Sabrina, Lakkis, Zaher, Nguyen, Thierry, Limat, Samuel, Borg, Christophe, Jary, Marine, Kim, Stefano, Nerich, Virginie
Format: Artigo
Sprog:Inglês
Udgivet: Libertas Academica 2016
Fag:
Original Research
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4933532/
https://ncbi.nlm.nih.gov/pubmed/27398042
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4137/CMO.S38335
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker